Here's Why We're Watching FluoGuide's (STO:FLUO) Cash Burn Situation
Jan 22
Have your own idea? Try our Stock Screener
Swedish (OMX) Biotech Industry Analysis
UpdatedFeb 15, 2025
DataAggregated Company Financials
Companies59
- 7D-3.9%
- 3M1.9%
- 1Y11.8%
- YTD-5.1%
Over the last 7 days, the Biotech industry has dropped 3.9%, driven by a pullback from Swedish Orphan Biovitrum of 3.6%. Meanwhile, Hamlet BioPharma actually outperformed within the industry, gaining 21% in the last week. This takes the industry's 12 month performance to a gain of 12%. Looking forward, earnings are forecast to grow by 29% annually.
Industry Valuation and Performance
Has the Swedish Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 16 Feb 2025 | SEK 207.6b | SEK 33.2b | SEK 414.7m | 45.7x | 500.4x | 6.2x |
| Tue, 14 Jan 2025 | SEK 215.4b | SEK 33.0b | -SEK 4,402,373,472.68 | 152.9x | -48.9x | 6.5x |
| Thu, 12 Dec 2024 | SEK 213.3b | SEK 33.0b | -SEK 4,445,586,677.61 | 142x | -48x | 6.5x |
| Sat, 09 Nov 2024 | SEK 214.6b | SEK 33.2b | -SEK 4,296,067,234.70 | 146.7x | -49.9x | 6.5x |
| Mon, 07 Oct 2024 | SEK 207.5b | SEK 31.4b | -SEK 5,524,008,836.26 | 48.6x | -37.6x | 6.6x |
| Wed, 04 Sep 2024 | SEK 213.9b | SEK 31.5b | -SEK 5,518,271,497.67 | 50.1x | -38.8x | 6.8x |
| Fri, 02 Aug 2024 | SEK 199.7b | SEK 31.4b | -SEK 5,420,661,930.09 | 44.4x | -36.8x | 6.4x |
| Sun, 30 Jun 2024 | SEK 196.6b | SEK 30.6b | -SEK 5,537,729,202.10 | 39.3x | -35.5x | 6.4x |
| Tue, 28 May 2024 | SEK 191.3b | SEK 30.6b | -SEK 5,406,201,941.09 | 39.2x | -35.4x | 6.3x |
| Thu, 25 Apr 2024 | SEK 178.8b | SEK 29.8b | -SEK 5,287,384,807.92 | 51.5x | -33.8x | 6x |
| Sat, 23 Mar 2024 | SEK 184.6b | SEK 29.8b | -SEK 5,638,389,957.11 | 58.7x | -32.7x | 6.2x |
| Mon, 19 Feb 2024 | SEK 177.4b | SEK 29.7b | -SEK 5,714,127,360.36 | 47.1x | -31x | 6x |
| Wed, 17 Jan 2024 | SEK 188.8b | SEK 28.7b | -SEK 1,199,908,981.00 | 59.7x | -157.3x | 6.6x |
| Fri, 15 Dec 2023 | SEK 174.7b | SEK 28.7b | -SEK 1,170,666,543.00 | 59x | -149.2x | 6.1x |
| Sun, 12 Nov 2023 | SEK 160.8b | SEK 28.7b | -SEK 1,265,936,686.00 | 50.6x | -127x | 5.6x |
| Tue, 10 Oct 2023 | SEK 156.8b | SEK 27.4b | -SEK 2,016,768,083.00 | 45.9x | -77.7x | 5.7x |
| Thu, 07 Sep 2023 | SEK 151.8b | SEK 27.4b | -SEK 1,966,519,055.00 | 49.8x | -77.2x | 5.6x |
| Sat, 05 Aug 2023 | SEK 153.8b | SEK 27.5b | -SEK 1,555,703,057.00 | 54.3x | -98.8x | 5.6x |
| Mon, 03 Jul 2023 | SEK 161.8b | SEK 26.4b | -SEK 1,317,402,647.00 | 45x | -122.8x | 6.1x |
| Wed, 31 May 2023 | SEK 165.2b | SEK 26.3b | -SEK 1,210,442,677.00 | 45.2x | -136.5x | 6.3x |
| Fri, 28 Apr 2023 | SEK 174.9b | SEK 25.5b | -SEK 2,144,449,920.00 | 37.1x | -81.6x | 6.9x |
| Sun, 26 Mar 2023 | SEK 165.5b | SEK 25.4b | -SEK 2,031,671,425.00 | 39.2x | -81.5x | 6.5x |
| Tue, 21 Feb 2023 | SEK 173.3b | SEK 25.4b | -SEK 2,098,281,283.00 | 37.8x | -82.6x | 6.8x |
| Thu, 19 Jan 2023 | SEK 179.5b | SEK 23.8b | -SEK 1,842,380,755.00 | 32.4x | -97.4x | 7.5x |
| Sat, 17 Dec 2022 | SEK 158.6b | SEK 23.8b | -SEK 1,838,040,816.00 | 31.2x | -86.3x | 6.7x |
| Mon, 14 Nov 2022 | SEK 156.0b | SEK 23.9b | -SEK 1,903,452,996.00 | 32.9x | -82x | 6.5x |
| Wed, 12 Oct 2022 | SEK 150.9b | SEK 22.9b | -SEK 3,333,549,724.00 | 30.5x | -45.3x | 6.6x |
| Fri, 09 Sep 2022 | SEK 157.2b | SEK 22.9b | -SEK 3,244,410,512.00 | 34.3x | -48.5x | 6.9x |
| Sun, 07 Aug 2022 | SEK 169.8b | SEK 22.7b | -SEK 3,502,700,170.00 | 35.8x | -48.5x | 7.5x |
| Tue, 05 Jul 2022 | SEK 155.5b | SEK 21.4b | -SEK 3,521,686,236.00 | 36.7x | -44.2x | 7.3x |
| Thu, 02 Jun 2022 | SEK 156.0b | SEK 21.4b | -SEK 3,524,128,445.00 | 43.3x | -44.3x | 7.3x |
| Sat, 30 Apr 2022 | SEK 153.5b | SEK 20.0b | -SEK 3,342,880,997.00 | 46x | -45.9x | 7.7x |
| Mon, 28 Mar 2022 | SEK 165.6b | SEK 19.7b | -SEK 3,081,724,978.00 | 50.5x | -53.7x | 8.4x |
| Wed, 23 Feb 2022 | SEK 154.6b | SEK 19.7b | -SEK 2,536,169,254.00 | 48.7x | -61x | 7.9x |
Price to Earnings Ratio
-61x
Current Industry PE
- Investors are optimistic on the Swedish Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 500x which is higher than its 3-year average PE of -78.8x.
- The industry is trading close to its 3-year average PS ratio of 6.6x.
Past Earnings Growth
- Total earnings for the Biotechs industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 19% per year.
- This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.
Industry Trends
Which industries have driven the changes within the Swedish Healthcare industry?
| SE Market | 2.63% | |
| Healthcare | -0.19% | |
| Biotech | -3.91% | |
| Biotech | -3.91% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| HAMLET B Hamlet BioPharma | SEK 3.75 | 21.4% +SEK 117.3m | 119.3% | PB9.5x | |
| DVYSR Devyser Diagnostics | SEK 137.00 | 2.6% +SEK 63.9m | 73.0% | PS10.5x | |
| IMMU Mendus | SEK 8.10 | 15.7% +SEK 55.4m | -12.9% | PS80.8x | |
| ABERA Abera Bioscience | SEK 5.60 | 46.6% +SEK 27.3m | -2.8% | PS5.8x | |
| ABLI Abliva | SEK 0.45 | 3.8% +SEK 26.6m | 89.5% | PS5294.5x |